214
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Development of a novel bi-coated combination capsule containing mosapride and probiotics for irritable bowel syndrome

, , , , , & show all
Pages 949-956 | Received 21 Feb 2014, Accepted 25 Jul 2014, Published online: 27 Aug 2014

References

  • Brandt L, Chey W, Foxx-Orenstein A, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1–S35
  • El-Serag B, Olden K, Bjorkaman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16:1171–1185
  • Gralnek M, Hays D, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654–660
  • Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:775–785
  • Mayer A, Naliboff D, Chang L. Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. Eur J Surg Suppl 2002;587:3–9
  • Neal R, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779–782
  • McKendrick W, Read W. Irritable bowel syndrome-post salmonella infection. J Infect 1994;29:1–3
  • Sanders S, Carter J, Hurlstone P, et al. Association of adult coeliac disease with irritable bowel syndrome: a case control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;3:1504–1508
  • Guyonnet D, Chassany O, Ducrotte P. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double blind, controlled trial. Aliment Pharmacol Ther 2007;26:475–486
  • Kim J, Vazquez Roque I, Camilleri M. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687–696
  • Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365–378
  • O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219–1225
  • McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975–980
  • Andersson H, Asp G, Bruce A, et al. Health effects of probiotics and prebiotics: a literature review on human studies. Scand J Nutr 2001;45:58–75
  • O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–551
  • Susanna R, Pirjo R. Protecting probiotic bacteria by microencapsulation: challenges for industrial applications. Eur Food Res Technol 2010;231:1–12
  • Aguirre M, Collins D. Lactic acid bacteria and human clinical infection. J Appl Bacteriol 1993;75:95–107
  • Hilton E, Isenberg D, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353–357
  • De Roos M, Katan B. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000;71:405–411
  • Islam A, Yun H, Choi J, Cho S. Microencapsulation of live probiotic bacteria. Microbiol Biotechnol 2010;20:1367–1377
  • Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium species. Immunol Cell Biol 2000;78:80–88
  • Charalampopoulos D, Pandiella SS, Webb C. Growth studies of potentially probiotic lactic acid bacteria in cereal-based substrates. J Appl Microbiol 2002;92:851–859
  • Chang S. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 2005;4:221–235
  • Sun M, Goosen F, O'Shea G. Microencapsulated cells as hormone delivery systems. Crit Rev Ther Drug Carrier Syst 1987;4:1–12
  • Kim G, Moon T, Lee M. The effects of probiotics on symptoms of irritable bowel syndrome. Korean J Gastroenterol 2006;47:413–419
  • Kanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991;42:335–337
  • Yoshida N, Kato S, Ito T. Oral bioavailability was 8% of the dose in dogs and 14% in monkeys, suggesting the extensive first-pass metabolism of mosapride. Drugs Future 1993;18:513–515
  • Yoshida N, Omoya H, Oka M, et al. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch Int Pharmacodyn Ther 1989;300:51–67
  • Karasawa T, Yoshida N, Furukawa K, et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL 24924. Eur J Pharmacol 1990;183:2181
  • Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680–686
  • Young N. How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci 2007;32:394–399
  • Gershon D, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397–414
  • Sakashita M, Mizuki Y, Yamaguchi T, et al. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in dogs and monkeys. Arzneimittelforschung 1993;43:864–866
  • Society of Toxicology (SOT). Guiding principles in the use of animals in toxicology. 2008. Available from: http://www.toxicology.org/ai/fa/guidingprinciples.pdf [last accessed 20 June 2012]
  • Newa M, Bhandari H, Li K, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007;343:228–237
  • Costa P, Sousa Lobo M. Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Dev Ind Pharm 2001;27:811–817
  • Keller A, Czerniuk P, Bertuola R, et al. Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study. Curr Med Res Opin 2011;27:2203–2211
  • Kim Y, Kim K, Suh K, et al. New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs. Int J Pharm 2011;415:129–139
  • Oh D, Park Y, Kang J, et al. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change. Drug Deliv 2011;18:46–53

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.